Bombesin, a bioactive peptide first identified in amphibian skin, is related to two mammalian peptides, gastrin-releasing peptide (GRP) and neuromedin B. A family of 3 GPCRs, including GRP-R (BB1), NMB-R (BB2) and BRS-3 (BB3), mediate the biological effects of the peptides (Ohki-Hamazaki et al., 2005). BB3 differs from the others by its low affinity for bombesin. Although an endogenous ligand for BB3 has yet to be identified, a synthetic nonselective bombesin-like peptide [D-Phe6, β-Ala11, Phe13, Nle14]-bombesin-(6-14)-amide activates BB3 with high potency. BB3-null mice develop mild obesity that can be alleviated by treatment with an antiobesity compound, the serotonin and noradrenaline reuptake inhibitor Sibutramine (Matsumoto and Iijima, 2003). Chemicon's cloned human BB3-expressing cell line is made in the Chem-1 host, which supports high levels of recombinant BB3 expression on the cell surface and contains high levels of the promiscuous G protein Gα15 to enhance coupling of the receptor to the calcium signaling pathway. Thus, the cell line is an ideal tool for screening for agonists and antagonists at BB3.